INI1 (SMARCB1)-deficient primary CNS malignant tumors

Clinical trials for INI1 (SMARCB1)-deficient primary CNS malignant tumors explained in plain language.

Never miss a new study

Get alerted when new INI1 (SMARCB1)-deficient primary CNS malignant tumors trials appear

Sign up with your email to follow new studies for INI1 (SMARCB1)-deficient primary CNS malignant tumors, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Not yet finished but already full! 1

New drug cocktail targets childhood cancers with missing proteins

Disease control Ongoing

This study tests a combination of three drugs—tazemetostat, nivolumab, and ipilimumab—in children with rare tumors that lack the INI1 or SMARCA4 proteins. The goal is to find a safe dose and see if the drugs can shrink tumors. About 49 children with specific tumor types are being…

Matched conditions: INI1 (SMARCB1)-DEFICIENT PRIMARY CNS MALIGNANT TUMORS

Phase 1/2 • Sponsor: Susan Chi, MD • Aim: Disease control

Last updated Jun 27, 2026 12:06 UTC

INI1 (SMARCB1)-deficient primary CNS malignant tumors

Get alerted when new INI1 (SMARCB1)-deficient primary CNS malignant tumors trials appear

New drug cocktail targets childhood cancers with missing proteins